Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 8/2020

01-08-2020 | Fentanyl | Review Article

Breakthrough cancer pain: review and calls to action to improve its management

Authors: C. Camps Herrero, N. Batista, N. Díaz Fernández, Y. Escobar Álvarez, A. Gonzalo Gómez, D. Isla Casado, A. Salud, J. Terrasa Pons, V. Guillem Porta

Published in: Clinical and Translational Oncology | Issue 8/2020

Login to get access

Abstract

In this paper, we review the current state of breakthrough cancer pain (BTcP) management. BTcP is a heterogeneous condition and a global problem for cancer patients. It is often managed suboptimally, which results in a negative outcome for patients, healthcare providers, and healthcare systems. Several barriers to the appropriate management of BTcP have been identified. These include, among others, an incomplete definition of BTcP, poor training of healthcare providers and patients alike, a lack of a multidisciplinary approach and the absence of specific protocols and tools. We provide some actions to help physicians and patients improve their approach to BTcP, including specific training, the design of easy-to-use tools for BTcP identification and assessment (such as checklists and pocket-sized cards), individualized treatment, and the use of multidisciplinary teams.
Literature
1.
Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, Ries LAG, et al. Annual report to the nation on the status of cancer, 1975–2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst. 2005;97(19):1407–27.PubMed
2.
Margarit C, Juliá J, López R, Anton A, Escobar Y, Casas A, et al. Breakthrough cancer pain-still a challenge. J Pain Res. 2012;5:559–66.PubMedPubMedCentral
3.
González-Escalada JR, Camba A, Casas A, Gascón P, Herruzo I, Núñez-Olarte JM, et al. Código de buena práctica para el control del dolor oncológico. Revista de la Sociedad Española del Dolor. 2011;18(2):98–117.
4.
5.
6.
Fallon M, Giusti R, Aielli F, Hoskin P, Rolke R, Sharma M, et al. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2018;29(Supplement_4):iv166–iv191.PubMed
7.
Mercadante S. Treating breakthrough pain in oncology. Expert Rev Anticancer Ther. 2018;18(5):445–9.PubMed
8.
Vellucci R, Mediati RD, Gasperoni S, Mammucari M, Marinangeli F, Romualdi P. Assessment and treatment of breakthrough cancer pain: from theory to clinical practice. J Pain Res. 2017;10:2147–55.PubMedPubMedCentral
9.
Mercadante S. Breakthrough pain in cancer patients: prevalence, mechanisms and treatment options. Curr Opin Anaesthesiol. 2015;28(5):559–64.PubMed
10.
Sabato AF. Idiopathic breakthrough pain: a new hypothesis. Clin Drug Investig. 2010;30(Suppl 2):27–9.PubMed
11.
Fortner BV, Demarco G, Irving G, Ashley J, Keppler G, Chavez J, et al. Description and predictors of direct and indirect costs of pain reported by cancer patients. J Pain Symptom Manage. 2003;25(1):9–18.PubMed
12.
Petzke F, Radbruch L, Zech D, Loick G, Grond S. Temporal presentation of chronic cancer pain: transitory pains on admission to a multidisciplinary pain clinic. J Pain Symptom Manage. 1999;17(6):391–401.PubMed
13.
Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain. 1999;81(1–2):129–34.PubMed
14.
Swanwick M, Haworth M, Lennard RF. The prevalence of episodic pain in cancer: a survey of hospice patients on admission. Palliat Med. 2001;15(1):9–18.PubMed
15.
Deandrea S, Corli O, Consonni D, Villani W, Greco MT, Apolone G. Prevalence of breakthrough cancer pain: a systematic review and a pooled analysis of published literature. J Pain Symptom Manage. 2014;47(1):57–76.PubMed
16.
Working Group Nientemale DEI, Vellucci R, Fanelli G, Pannuti R, Peruselli C, Adamo S, et al. What to do, and What not to do, When diagnosing and dreating breakthrough cancer pain (BTcP): expert opinion. Drugs. 2016;76(3):315–30.PubMedCentral
17.
Yang P, Cheville AL, Wampfler JA, Garces YI, Jatoi A, Clark MM, et al. Quality of life and symptom burden among long-term lung cancer survivors. J Thorac Oncol. 2012;7(1):64–70.PubMedPubMedCentral
18.
American Pain Foundation n. Breakthrough cancer pain: mending the break in the continuum of care. J Pain Palliat Care Pharmacother. 2011;25(3):252–64.
19.
Davies A, Buchanan A, Zeppetella G, Porta-Sales J, Likar R, Weismayr W, et al. Breakthrough cancer pain: an observational study of 1000 European oncology patients. J Pain Symptom Manage. 2013;46(5):619–28.PubMed
20.
Mantyh PW. Cancer pain and its impact on diagnosis, survival and quality of life. Nat Rev Neurosci. 2006;7(10):797–809.PubMed
21.
Perez-Hernandez C, Jimenez-Lopez AJ, Sanz-Yague A, Mar-Medina J, Larranaga I, Soler-Lopez B. Observational study evaluating the economic impact of breakthrough pain in cancer patients in clinical practice in Spain: the IMDI study. Pain Ther. 2018;7(2):227–40.PubMedPubMedCentral
22.
Ruggeri M, Turriziani A, Oradei M. Cost-effectiveness analysis of transnasal fentanyl citrate for the treatment of breakthrough cancer pain. Expert Rev Pharmacoecon Outcomes Res. 2014;14(3):459–64.PubMed
23.
Fortner BV, Okon TA, Portenoy RK. A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain. J Pain. 2002;3(1):38–44.PubMed
24.
Fortner BV, Okon TA, Ashley J, Kepler G, Chavez J, Tauer K, et al. The zero acceptance of pain (ZAP) quality improvement project: evaluation of pain severity, pain interference, global quality of life, and pain-related costs. J Pain Symptom Manage. 2003;25(4):334–43.PubMed
25.
Mularski RA, White-Chu F, Overbay D, Miller L, Asch SM, Ganzini L. Measuring pain as the 5th vital sign does not improve quality of pain management. J Gen Intern Med. 2006;21(6):607–12.PubMedPubMedCentral
26.
Camps Herrero C, Reina Zoilo JJ, Monge Martín D, Caballero Martínez F, Guillem Porta V, Aranda Aguilar E, et al. Active study: undetected prevalence and clinical inertia in the treatment of breakthrough cancer pain (BTcP). Clin Transl Oncol. 2019;21(3):380–90.PubMed
27.
Escobar Álvarez Y, Biete i Solà A, Camba Rodríguez M, Gálvez Mateos R, Mañas Rueda A, Rodríguez Sánchez CA, et al. Diagnóstico y tratamiento del dolor irruptivo oncológico: recomendaciones de consenso. Revista de la Sociedad Española del Dolor. 2013;20(2):61–8.
28.
García-Mata J, Álamo C, de Castro J, Contreras J, Gálvez R, Jara C, et al. A survey of perceptions, attitudes, knowledge and practices of medical oncologists about cancer pain management in Spain. Clin Transl Oncol. 2018;20(8):1061–71.PubMed
29.
Association for Palliative Medicine of Great B 2009 The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland Eur J Pain. 13 4 331 338
30.
Mercadante S, Portenoy RK. Breakthrough cancer pain: twenty-five years of study. Pain. 2016;157(12):2657–63.PubMed
31.
Løhre ET, Klepstad P, Bennett MI, Brunelli C, Caraceni A, Fainsinger RL, et al. From "breakthrough" to "episodic" cancer pain? A European association for palliative care research network expert delphi survey toward a common terminology and classification of transient cancer pain exacerbations. J Pain Symptom Manage. 2016;51(6):1013–9.PubMed
32.
Jara C, Del Barco S, Gravalos C, Hoyos S, Hernandez B, Munoz M, et al. SEOM clinical guideline for treatment of cancer pain (2017). Clin Transl Oncol. 2018;20(1):97–107.PubMed
33.
Kwon JH. Overcoming barriers in cancer pain management. J Clin Oncol. 2014;32(16):1727–33.PubMed
34.
Breivik H, Cherny N, Collett B, de Conno F, Filbet M, Foubert AJ, et al. Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann Oncol. 2009;20(8):1420–33.PubMed
35.
Carulla Torrent J, Jara Sánchez C, Sanz Ortiz J, Batista López N, Camps Herrero C, Cassinello Espinosa J, et al. Oncologists' perceptions of cancer pain management in Spain: the real and the ideal. Eur J Pain. 2007;11(3):352–9.PubMed
36.
Kwon JH, Oh SY, Chisholm G, Lee J-A, Lee JJ, Park KW, et al. Predictors of high score patient-reported barriers to controlling cancer pain: a preliminary report. Support Care Cancer. 2013;21(4):1175–83.PubMed
37.
Fallon M, Giusti R, Aielli F, Hoskin P, Rolke R, Sharma M, et al. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines†. Ann Oncol. 2018;29(Supplement_4):iv166–iv191.PubMed
38.
Vellucci R. Breakthrough cancer pain. Eur J Oncol. 2015;20(suppl 1):11–2.
39.
Boceta J, De la Torre A, Samper D, Farto M, Sánchez-de la Rosa R. Consensus and controversies in the definition, assessment, treatment and monitoring of BTcP: results of a Delphi study. Clin Transl Oncol. 2016;18(11):1088–97.PubMedPubMedCentral
40.
Webber K, Davies AN, Zeppetella G, Cowie MR. Development and validation of the breakthrough pain assessment tool (BAT) in cancer patients. J Pain Symptom Manage. 2014;48(4):619–31.PubMed
41.
Webber K, Davies AN, Cowie MR. Accuracy of a diagnostic algorithm to diagnose breakthrough cancer pain as compared with clinical assessment. J Pain Symptom Manage. 2015;50(4):495–500.PubMed
42.
Fallon M, Walker J, Colvin L, Rodriguez A, Murray G, Sharpe M, et al. Pain management in cancer center inpatients: a cluster randomized trial to evaluate a systematic integrated approach-the edinburgh pain assessment and management tool. J Clin Oncol. 2018;36(13):1284–90.PubMedPubMedCentral
43.
Jacobsen PB, Snyder CF. Improving pain assessment and management in routine oncology practice: the role of implementation research. J Clin Oncol. 2018;36(13):1272–4.PubMed
44.
Porta-Sales J, Garzón Rodríguez C, Julià Torras J, Casals MM. Dolor irruptivo en cáncer. Med Clin (Barc). 2010;135(6):280–5.PubMed
45.
Vissers DCJ, Lenre M, Tolley K, Jakobsson J, Sendersky V, Jansen JP. An economic evaluation of short-acting opioids for treatment of breakthrough pain in patients with cancer. Value Health. 2011;14(2):274–81.PubMed
46.
Caraceni A, Davies A, Poulain P, Cortes-Funes H, Panchal SJ, Fanelli G. Guidelines for the management of breakthrough pain in patients with cancer. J Natl Compr Canc Netw. 2013;11(Suppl 1):S29–36.PubMed
47.
Porta-Sales J, Pérez C, Escobar Y, Martínez V. Diagnosis and management of breakthrough cancer pain: Have all the questions been resolved? A Delphi-based consensus assessment (DOIRON). Clin Transl Oncol. 2016;18(9):945–54.PubMed
48.
Álamo C, Zaragozá-Arnáez C, Noriega-Matanza C, M-Torres L. Fentanilo: una molécula y múltiples formulaciones galénicas de trascendencia clínica en el tratamiento del dolor irruptivo oncológico. Revista de la Sociedad Española del Dolor. 2017;24:188–200.
49.
Rauck R, North J, Gever LN, Tagarro I, Finn AL. Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study. Ann Oncol. 2010;21(6):1308–14.PubMed
50.
Buchanan A, Davies A, Geerling J. Breakthrough cancer pain: the role of the nurse. Int J Palliat Nurs. 2014;20(3):126–9.PubMed
51.
Vallerand AH, Musto S, Polomano RC. Nursing's role in cancer pain management. Curr Pain Headache Rep. 2011;15(4):250–62.PubMed
52.
Wengstrom Y, Geerling J, Rustoen T. European Oncology Nursing Society breakthrough cancer pain guidelines. Eur J Oncol Nurs. 2014;18(2):127–31.PubMed
53.
Mercadante S, Adile C, Torta R, Varetto A, Fulfaro F, Giarratano A, et al. Meaningful cut-off pain intensity for breakthrough pain changes in advanced cancer patients. Curr Med Res Opin. 2013;29(1):93–7.PubMed
54.
Mercadante S, Cuomo A. Breakthrough cancer pain: ten commandments. Value Health. 2016;19(5):531–6.PubMed
55.
56.
López López R, Camps Herrero C, Khosravi-Shahi P, Guillem Porta V, Carrato Mena A, Garcia-Foncillas J, et al. Oncologist's knowledge and implementation of guidelines for breakthrough cancer pain in Spain: CONOCE study. Clin Transl Oncol. 2018;20(5):613–8.PubMed
57.
O'Hagan P, Mercadante S. Breakthrough cancer pain: the importance of the right treatment at the right time. Eur J Pain. 2018;22(7):1362–74.PubMed
58.
Caraceni A, Martini C, Zecca E, Portenoy RK, Ashby MA, Hawson G, et al. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med. 2004;18(3):177–83.PubMed
59.
60.
Davies AN, Elsner F, Filbet MJ, Porta-Sales J, Ripamonti C, Santini D, et al. Breakthrough cancer pain (BTcP) management: a review of international and national guidelines. BMJ Support Palliat Care. 2018;8(3):241–9.PubMed
61.
Camps C, Rubio ED, Lopez R, Carrato A, Gascon P, Margarita F, et al. The quality oncology practice initiative program: experience in Spain. J Clin Oncol. 2017;35(8_suppl):214.
62.
Dubois MY, Follett KA. Pain medicine: The case for an independent medical specialty and training programs. Acad Med. 2014;89(6):863–8.PubMed
63.
Sabia M, Weaver M, Gessman R, Kalariya J. Update on the importance of medical education in the changing field of pain medicine. J Anesthesia Patient Care. 2017;2:1–5.
64.
Kuip EJ, Zandvliet ML, Koolen SL, Mathijssen RH, van der Rijt CC. A review of factors explaining variability in fentanyl pharmacokinetics; focus on implications for cancer patients. Br J Clin Pharmacol. 2017;83(2):294–313.PubMed
65.
Daeninck P, Gagnon B, Gallagher R, Henderson JD, Shir Y, Zimmermann C, et al. Canadian recommendations for the management of breakthrough cancer pain. Curr Oncol. 2016;23(2):96–108.PubMedPubMedCentral
Metadata
Title
Breakthrough cancer pain: review and calls to action to improve its management
Authors
C. Camps Herrero
N. Batista
N. Díaz Fernández
Y. Escobar Álvarez
A. Gonzalo Gómez
D. Isla Casado
A. Salud
J. Terrasa Pons
V. Guillem Porta
Publication date
01-08-2020
Publisher
Springer International Publishing
Keyword
Fentanyl
Published in
Clinical and Translational Oncology / Issue 8/2020
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-019-02268-8

Other articles of this Issue 8/2020

Clinical and Translational Oncology 8/2020 Go to the issue

Research Article

IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma

Research Article

Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer

Research Article

Survey of treatment recommendations for elderly patients with glioblastoma

Review Article

Maintenance treatment in metastatic colorectal cancer: in search of the best strategy

Research Article

Efficacy of capecitabine when used concomitantly with proton pump inhibitors in cancer patients: a systematic review

Research Article

Different variables predict the outcome of patients with synchronous versus metachronous metastases of colorectal cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits